Cancer

News

Janssen J&J Johnson and Johnson pharmaceutical companies

J&J buys novel lung cancer drug from South Korea's Yuhan

Janssen Biotech has bought Yuhan’s Lazertinib, a novel clinical-stage therapeutic candidate for the treatment of patients with non-small cell lung cancer (NSCLC).

News

BMS and Infinity trial immunotherapy combo in bladder cancer

Bristol-Myers Squibb has broadened a collaboration with Infinity Pharmaceuticals as it seeks to find combinations that boost the potency of its cancer immunotherapy, Opdivo.

News

Blurred background for histopathology-related presentation. Stained histological tissue samples on glass, fixed tissue, automatic pipette and other work-related tools. Toned image, text space.

AI pathology project awarded £10.1m government funding

A digital pathology and artificial intelligence collaboration, with partners including Roche Diagnostics and Microsoft, has been awarded £10.1 million from a government-backed agency to exp

News

FDA green lights Pfizer's Lorbrena for aggressive lung cance...

Pfizer’s drug Lorbrena (lorlatinib) can be used to treat certain types of advanced lung cancer.

News

Zytiga generics looming as US court nixes J&J patent

Johnson & Johnson has lost another round in its patent defence for prostate cancer blockbuster Zytiga, raising the possibility that generics could launch in the coming days.

Views & Analysis